HRP20170104T1 - Derivati tipa azaindazola ili diazaindazola za liječenje boli - Google Patents
Derivati tipa azaindazola ili diazaindazola za liječenje boli Download PDFInfo
- Publication number
- HRP20170104T1 HRP20170104T1 HRP20170104TT HRP20170104T HRP20170104T1 HR P20170104 T1 HRP20170104 T1 HR P20170104T1 HR P20170104T T HRP20170104T T HR P20170104TT HR P20170104 T HRP20170104 T HR P20170104T HR P20170104 T1 HRP20170104 T1 HR P20170104T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- compound
- use according
- image
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj sljedeće opće formule (I):
[image]
ili farmaceutski prihvatljiva sol ili njegov solvat, njegov tautomer ili stereoizomer ili smjesa njegovih stereoizomera u bilo kojim omjerima, kao što je smjesa enantiomera, osobito racemična smjesa,
u kojoj:
- Y1 i Y4 svaki predstavlja, neovisno jedan od drugog, CH skupinu ili dušikov atom uz uvjet da najmanje jedan od Y1 i Y4 predstavlja dušikov atom,
- Y2 predstavlja C-X-Ar skupinu,
- Y3 predstavlja C-W skupinu,
- Ar predstavlja arilnu ili heteroarilnu skupinu koja može biti supstituirana s jednom ili više skupina odabranih od sljedećih: atom halogena, (C1-C6)alkil, (C1-C6)halogenalkil, (C1-C6)halogenalkoksi,
(C1-C6)halogentioalkoksi, CN, NO2, OR11, SR12, NR13R14, CO2R15, CONR16R17, SO2R18, SO2NR19R20, COR21, NR22COR23, NR24SO2R25, te R26NR27R28 i/ili može biti fuzioniran za heterocikličku skupinu,
- X predstavlja divalentnu skupinu odabranu od sljedećih: O, S, S(O), S(O)2, NR4, S(NR4), S(O)(NR4), S(O)2(NR4), NR4S, NR4S(O), NR4S(O)2, CH2, CH2S, CH2S(O), CH2S(O)2, SCH2, S(O)CH2, S(O)2CH2, CH2CH2, CH=CH, C=C, CH2O, OCH2, NR4CH2 te CH2NR4,
- W predstavlja R5, SR5, OR5 ili NR5R6 skupinu,
- U predstavlja CH2 ili NH skupinu, gdje jedan ili više vodikovih atoma mogu biti zamijenjeni
(C1-C6)alkilnom skupinom,
- V predstavlja C(O), C(S) ili CH2,
- n predstavlja 0 ili 1,
- R1 predstavlja vodikov atom ili OR7 ili NR7R8 skupinu,
- R2 predstavlja vodikov atom, heterocikličku skupinu koja može biti supstituirana, NO2, OR9 ili NR9R10,
- R3, R4, R11 do R25 te R27 do R28 svaki predstavlja, neovisno jedan od drugog, vodikov atom ili
(C1-C6)alkilnu skupinu,
- R5 i R6 svaki predstavlja, neovisno jedan od drugog, vodikov atom ili (C1-C6)alkilnu skupinu, arilnu skupinu koja može supstituirana ili benzilnu skupinu koja može supstituirana,
- R7, R8, R9 i R10 svaki predstavlja, neovisno jedan od drugog, vodikov atom ili (C1-C6)alkilnu skupinu koja može biti supstituirana ili (C3-C12)cikloalkilnu skupinu ili heterocikličku skupinu koja može biti supstituirana, te
- R26 predstavlja (C1-C6)alkilnu skupinu,
za upotrebu u liječenju ili sprječavanju boli.
2. Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time da bol jest nociceptivna bol, upalna bol, neuropatska bol, idiopatska bol ili psihogena bol, preferirano upalna bol ili neuropatska bol.
3. Spoj prema patentnom zahtjevu 1 ili 2, za bol kao posljedicu karcinoma, ozljede živca ili reumatskih bolesti.
4. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da
- Y1 = CH ili N, te
- Y4 = N.
5. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time da
- Y1 predstavlja CH skupinu, te
- Y4predstavlja dušikov atom.
6. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time da X predstavlja dvovalentnu skupinu odabranu od sljedećih: S, S(O), S(O)2, NR4, CH2, CH2S, CH2S(O), CH2S(O)2, CH2O, CH2NR4, NHS(O)2, SCH2, S(O)CH2, S(O)2CH2, S(O)2NH, OCH2, NR4CH2, CH2CH2, CH=CH, te C=C; posebno od sljedećih: S, S(O), S(O)2, NR4, CH2, SCH2, S(O)CH2, S(O)2CH2, S(O)2NH, CH2CH2, C=C, OCH2, te NR4CH2; a još posebnije od sljedećih: S, S(O)2, CH2, SCH2, S(O)2CH2, S(O)2NH, CH2CH2 te C=C, gdje je prvi atom ovih skupina veza na C atom lanca C-X-Ar.
7. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time da Ar predstavlja arilnu skupinu, kao što je fenilna, koja može biti supstituirana jednom ili više skupina odabranih od sljedećih: atom halogena, (C1-C6)alkil, (C1-C6)halogenalkil, (C1-C6)halogenalkoksi, (C1-C6)halogentioalkoksi, CN, NO2, OR11, SR12, NR13R14, CO2R15, te CONR16R17, SO2R18, SO2NR19R20, COR21, NR22COR23 ili NR24SO2R25; ili piridinska skupina.
8. Spoj za upotrebu prema patentnom zahtjevu 7, naznačen time da Ar predstavlja skupinu odabranu od sljedećih skupina:
[image]
9. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time da W predstavlja R5, SR5, OR5 ili NR5R6 skupinu, gdje R5 i R6 predstavljaju, neovisno jedan od drugog, vodikov atom ili (C1-C6)alkilnu skupinu.
10. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time da
- R3 = H,
- U = CH2 ili NH,
- V = C(O) ili C(S), a osobito C(O), te
- n = 0 ili 1, a osobito 0.
11. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time da R1predstavlja vodikov atom ili NR7R8 skupinu, gdje R7 predstavlja vodikov atom te R8 predstavlja (C3-C12)cikloalkilnu skupinu koja može biti supstituirana ili heterocikličku skupinu koja može biti supstituirana.
12. Spoj za upotrebu prema patentnom zahtjevu 11, naznačen time da R1 predstavlja jednu od sljedećih skupina: H,
[image]
13. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time da R2predstavlja NO2, NR9R10 ili heterocikličku skupinu koja može biti supstituirana s (C1-C6)alkilom ili NH2.
14. Spoj za upotrebu prema patentnom zahtjevu 13, naznačen time da R2 predstavlja jednu od sljedećih skupina: NH2, NH(CH2)3NMe2, NMe(CH2)3NMe2, NO2,
[image]
15. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time da je odabran od sljedećih spojeva:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
16. Farmaceutski pripravak koja sadrži najmanje jedan farmaceutski prihvatljiv ekscipijens i jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 15 kao aktivni sastojak, za upotrebu u liječenju ili sprječavanju boli.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305922.2A EP2689778A1 (en) | 2012-07-27 | 2012-07-27 | Derivatives of azaindoles or diazaindoles for treating pain |
| EP13745813.9A EP2877177B1 (en) | 2012-07-27 | 2013-07-29 | Derivatives of azaindazole or diazaindazole type for treating pain |
| PCT/EP2013/065907 WO2014016433A1 (en) | 2012-07-27 | 2013-07-29 | Derivatives of azaindazole or diazaindazole type for treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170104T1 true HRP20170104T1 (hr) | 2017-03-24 |
Family
ID=48948392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170104TT HRP20170104T1 (hr) | 2012-07-27 | 2013-07-29 | Derivati tipa azaindazola ili diazaindazola za liječenje boli |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9381195B2 (hr) |
| EP (2) | EP2689778A1 (hr) |
| JP (2) | JP6456823B2 (hr) |
| KR (1) | KR102120505B1 (hr) |
| CN (1) | CN104684554B (hr) |
| AU (1) | AU2013294920B2 (hr) |
| BR (1) | BR112015001502B1 (hr) |
| CA (1) | CA2879595C (hr) |
| CY (1) | CY1118478T1 (hr) |
| DK (1) | DK2877177T3 (hr) |
| ES (1) | ES2612349T3 (hr) |
| HR (1) | HRP20170104T1 (hr) |
| HU (1) | HUE032919T2 (hr) |
| IL (1) | IL236917A (hr) |
| LT (1) | LT2877177T (hr) |
| MA (1) | MA37866B1 (hr) |
| MX (1) | MX363605B (hr) |
| MY (1) | MY183398A (hr) |
| NZ (1) | NZ705253A (hr) |
| PL (1) | PL2877177T3 (hr) |
| PT (1) | PT2877177T (hr) |
| RS (1) | RS55646B1 (hr) |
| RU (1) | RU2640046C2 (hr) |
| SI (1) | SI2877177T1 (hr) |
| TN (1) | TN2015000034A1 (hr) |
| UA (1) | UA116107C2 (hr) |
| WO (1) | WO2014016433A1 (hr) |
| ZA (1) | ZA201501209B (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| NZ604708A (en) | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| WO2015143652A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| AU2015328307B2 (en) * | 2014-10-06 | 2019-11-21 | Apm Therapeutics 1, Inc. | Triazolopyridine compounds and methods for the treatment of cystic fibrosis |
| HUE061448T2 (hu) | 2014-11-16 | 2023-07-28 | Array Biopharma Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája |
| US10336707B2 (en) | 2014-12-16 | 2019-07-02 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| ES2987474T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida |
| ES2836222T3 (es) | 2016-05-18 | 2021-06-24 | Loxo Oncology Inc | Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US10246462B2 (en) | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018079759A1 (ja) * | 2016-10-31 | 2018-05-03 | 塩野義製薬株式会社 | ＴｒｋＡ阻害活性を有する縮合複素環および縮合炭素環誘導体 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CA3098988A1 (en) * | 2018-05-02 | 2019-11-07 | Jw Pharmaceutical Corporation | Heterocycle derivative |
| KR102129114B1 (ko) | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
| EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
| CN110105356B (zh) * | 2019-05-31 | 2022-04-01 | 四川国康药业有限公司 | 一种氮杂吲哚类化合物及其制备方法和用途 |
| EP4722211A1 (en) * | 2023-05-24 | 2026-04-08 | Changchun Genescience Pharmaceutical Co., Ltd. | Fgfr2/3 selective inhibitor, pharmaceutical composition and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0970084T3 (da) | 1997-03-19 | 2003-09-29 | Abbott Gmbh & Co Kg | Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase |
| EP1215208B1 (en) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
| AU2001262597B2 (en) | 2000-06-22 | 2005-10-20 | Pfizer Inc. | Process for the preparation of pyrazolopyrimidinones |
| SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| RU2008110941A (ru) * | 2005-08-25 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US20100056516A1 (en) | 2006-07-17 | 2010-03-04 | Williams Peter D | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| EP2120932B1 (en) * | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| WO2008112695A2 (en) * | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| PH12013501594A1 (en) | 2007-07-20 | 2014-05-12 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| EP2373626B1 (en) | 2008-12-18 | 2016-08-24 | Nerviano Medical Sciences S.r.l. | Substituted indazole derivatives active as kinase inhibitors |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
-
2012
- 2012-07-27 EP EP12305922.2A patent/EP2689778A1/en not_active Withdrawn
-
2013
- 2013-07-29 JP JP2015523576A patent/JP6456823B2/ja active Active
- 2013-07-29 AU AU2013294920A patent/AU2013294920B2/en not_active Ceased
- 2013-07-29 MX MX2015001009A patent/MX363605B/es unknown
- 2013-07-29 NZ NZ705253A patent/NZ705253A/en unknown
- 2013-07-29 CA CA2879595A patent/CA2879595C/en active Active
- 2013-07-29 KR KR1020157004735A patent/KR102120505B1/ko not_active Expired - Fee Related
- 2013-07-29 PL PL13745813T patent/PL2877177T3/pl unknown
- 2013-07-29 HU HUE13745813A patent/HUE032919T2/hu unknown
- 2013-07-29 LT LTEP13745813.9T patent/LT2877177T/lt unknown
- 2013-07-29 RU RU2015106434A patent/RU2640046C2/ru active
- 2013-07-29 BR BR112015001502-6A patent/BR112015001502B1/pt active IP Right Grant
- 2013-07-29 WO PCT/EP2013/065907 patent/WO2014016433A1/en not_active Ceased
- 2013-07-29 US US14/417,507 patent/US9381195B2/en active Active
- 2013-07-29 RS RS20170095A patent/RS55646B1/sr unknown
- 2013-07-29 ES ES13745813.9T patent/ES2612349T3/es active Active
- 2013-07-29 MY MYPI2015700206A patent/MY183398A/en unknown
- 2013-07-29 SI SI201330496A patent/SI2877177T1/sl unknown
- 2013-07-29 DK DK13745813.9T patent/DK2877177T3/en active
- 2013-07-29 UA UAA201501614A patent/UA116107C2/uk unknown
- 2013-07-29 PT PT137458139T patent/PT2877177T/pt unknown
- 2013-07-29 CN CN201380049411.3A patent/CN104684554B/zh active Active
- 2013-07-29 EP EP13745813.9A patent/EP2877177B1/en active Active
- 2013-07-29 HR HRP20170104TT patent/HRP20170104T1/hr unknown
-
2015
- 2015-01-23 TN TNP2015000034A patent/TN2015000034A1/fr unknown
- 2015-01-25 IL IL236917A patent/IL236917A/en active IP Right Grant
- 2015-02-23 ZA ZA2015/01209A patent/ZA201501209B/en unknown
- 2015-02-23 MA MA37866A patent/MA37866B1/fr unknown
-
2017
- 2017-01-23 CY CY20171100091T patent/CY1118478T1/el unknown
-
2018
- 2018-10-24 JP JP2018200317A patent/JP6732855B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170104T1 (hr) | Derivati tipa azaindazola ili diazaindazola za liječenje boli | |
| HRP20180524T1 (hr) | Derivati tipa azaindazola ili diazaindazola kao lijek | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| SI3099687T1 (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
| RU2011151835A (ru) | Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ | |
| RU2012116584A (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
| JP2013010793A5 (hr) | ||
| AR060316A1 (es) | Azaindoles de utilidad como inhibidores de janus quinasas | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| JP2015522650A5 (hr) | ||
| RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
| AR061583A1 (es) | Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih. | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| JP2013502430A5 (hr) | ||
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| RU2012144317A (ru) | Противоинфекционные соединения | |
| AR082218A1 (es) | Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion | |
| JP2013526559A5 (hr) | ||
| WO2018075959A4 (en) | Methods using hdac11 inhibitors | |
| RU2011146641A (ru) | Производные имидазолидин-2,4-диона и их применение в качестве лекарственного средства против рака | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| RU2008143556A (ru) | Производные тиазолилдигидроиндазола в качестве ингибиторов протеинкиназ | |
| RU2016144076A (ru) | Сильнодействующие и селективные ингибиторы вируса гепатита с |